| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
There is no specific biological target. The compound may be hydrolyzed by cholesterol esterase to free cholesterol and nervonic acid. Nervonic acid is involved in sphingolipid synthesis and myelin sheath repair, but the ester itself is not an active drug.
|
|---|---|
| ln Vitro |
In cell-free assays, cholesterol nervonate is a substrate for pancreatic cholesterol esterase, with hydrolysis rate dependent on chain length. It can also be used to study the incorporation of nervonic acid into lipid bilayers or lipoproteins. No direct enzyme activation or inhibition is reported.
|
| ln Vivo |
Dietary cholesterol nervonate may increase plasma cholesterol levels in animal models, as the ester is hydrolyzed and absorbed. However, there is no specific in vivo pharmacological activity. It is not a therapeutic agent; rather, it is a biomarker for certain metabolic conditions.
|
| Enzyme Assay |
For cholesterol esterase assay: Cholesterol nervonate (0.1-1 mM) is incubated with cholesterol esterase (0.1 U/mL) in 0.1 M phosphate buffer (pH 7.0) containing 0.5% Triton X-100 and 1 mM taurocholate. The release of free fatty acids is measured by colorimetric assay (e.g., NEFA kit) or by HPLC after 30-60 minutes at 37degC.
|
| Cell Assay |
No specific cellular protocol. For lipid metabolism studies, hepatocytes or macrophages are treated with cholesterol nervonate (10-100 uM) complexed with albumin or cyclodextrin. Cellular cholesterol and nervonic acid levels are analyzed by GC-MS. It may be used to model cholesterol ester accumulation in foam cells.
|
| Animal Protocol |
In animal studies, cholesterol nervonate (e.g., 50-200 mg/kg) can be administered by oral gavage in oil to mice. Blood is collected after 2-6 hours to measure plasma cholesterol and nervonate levels. Long-term feeding studies (2-4 weeks) assess its effect on liver lipid profiles.
|
| ADME/Pharmacokinetics |
PK: After oral administration, cholesterol nervonate is hydrolyzed by pancreatic cholesterol esterase. The resulting cholesterol and nervonic acid are absorbed, re-esterified, and incorporated into chylomicrons. Peak plasma levels occur at 2-4 hours. The terminal half-life of nervonic acid is several days in tissues.
|
| Toxicity/Toxicokinetics |
General toxicity: Cholesterol nervonate is generally considered non-toxic at nutritional levels. It is a natural component of some foods (e.g., fish oil, nuts). At very high doses, it may contribute to hypercholesterolemia. Standard safety for lipids applies; no acute toxicity reported.
|
| Additional Infomation |
Cholesteryl nervonate is the (15Z)-stereoisomer of teicocerenoic acid cholesterol ester.
Cholesterol nervonate is used as an analytical standard for the quantification of cholesterol esters in biological samples by GC or LC-MS. It is also used in studies of fatty acid transport and metabolism. Nervonic acid is of interest for its potential in treating demyelinating diseases. This product is for research use only. |
| Molecular Formula |
C51H90O2
|
|---|---|
| Molecular Weight |
735.26
|
| Exact Mass |
734.694
|
| CAS # |
60758-73-8
|
| PubChem CID |
53477888
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
0.94g/cm3
|
| Boiling Point |
729.2ºC at 760 mmHg
|
| Flash Point |
396.5ºC
|
| Index of Refraction |
1.508
|
| LogP |
16.317
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
2
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
53
|
| Complexity |
1070
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
CCCCCCCC/C=C/CCCCCCCCCCCCCC(=O)O[C@H]1CC[C@@]2([C@H]3CC[C@]4([C@H]([C@@H]3CC=C2C1)CC[C@@H]4[C@H](C)CCCC(C)C)C)C
|
| InChi Key |
PUKCXSHDVCMMAN-FYGHJIOESA-N
|
| InChi Code |
InChI=1S/C51H90O2/c1-7-8-9-10-11-12-13-14-15-16-17-18-19-20-21-22-23-24-25-26-27-31-49(52)53-44-36-38-50(5)43(40-44)32-33-45-47-35-34-46(42(4)30-28-29-41(2)3)51(47,6)39-37-48(45)50/h14-15,32,41-42,44-48H,7-13,16-31,33-40H2,1-6H3/b15-14-/t42-,44+,45+,46-,47+,48+,50+,51-/m1/s1
|
| Chemical Name |
[(3S,8S,9S,10R,13R,14S,17R)-10,13-dimethyl-17-[(2R)-6-methylheptan-2-yl]-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl] (Z)-tetracos-15-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.3601 mL | 6.8003 mL | 13.6006 mL | |
| 5 mM | 0.2720 mL | 1.3601 mL | 2.7201 mL | |
| 10 mM | 0.1360 mL | 0.6800 mL | 1.3601 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
